Skip to content
Blerp – Lifestyle
Author:
Castle Biosciences, Inc.
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
October 15, 2026
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett’s Esophagus
October 12, 2026
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
September 30, 2026
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett’s Esophagus
September 28, 2026
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
September 24, 2026
Castle Biosciences to Open New Laboratory Facility in Scottsdale
September 22, 2026
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett’s Esophagus
September 15, 2026
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
September 9, 2026
Castle Biosciences to Participate in Upcoming Investor Conferences
August 20, 2026
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
August 17, 2026
1
2
3
Next Page
→